Single chain variable fragments against beta-amyloid (Abeta) can inhibit Abeta aggregation and prevent abeta-induced neurotoxicity.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Biochemistry

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 15170333
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of different anti-Abeta antibodies on Abeta fibrillogenesis as assessed by atomic force microscopy.

  2004cited by this paper
• Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid.

  2003cited by this paper
• Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation.

  2003cited by this paper
• Spying on HIV with SPR.

  2003cited by this paper
• Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease.

  2003cited by this paper
• Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report

  2003cited by this paper
• Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice.

  2003cited by this paper
• Glutamate and Amyloid β-Protein Rapidly Inhibit Fast Axonal Transport in Cultured Rat Hippocampal Neurons by Different Mechanisms

  2003cited by this paper
• Human anti-beta-amyloid antibodies block beta-amyloid fibril formation and prevent beta-amyloid-induced neurotoxicity.

  2003cited by this paper
• Vaccination with amyloid-beta peptide induces autoimmune encephalomyelitis in C57/BL6 mice.

  2003cited by this paper
• Epitope and isotype specificities of antibodies to β-amyloid peptide for protection against Alzheimer's disease-like neuropathology

  2003cited by this paper
• Microglia-Mediated Nitric Oxide Cytotoxicity of T Cells Following Amyloid β-Peptide Presentation to Th1 Cells 1

  2003cited by this paper
• Evidence for peripheral clearance of cerebral Abeta protein following chronic, active Abeta immunization in PSAPP mice.

  2003cited by this paper
• Unfolding the role of protein misfolding in neurodegenerative diseases

  2003cited by this paper
• In Vitro Characterization of Conditions for Amyloid-β Peptide Oligomerization and Fibrillogenesis*

  2003cited by this paper
• Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis

  2003cited by this paper
• NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo.

  2003cited by this paper
• Intracerebroventricular passive immunization with anti‐Aβ antibody in Tg2576

  2003cited by this paper
• Alternate aggregation pathways of the Alzheimer beta-amyloid peptide: Abeta association kinetics at endosomal pH.

  2003cited by this paper
• Intersegmental interactions in supercoiled DNA: atomic force microscope study.

  2003cited by this paper
• The generation and characterization of potentially therapeutic Abeta antibodies in mice: differences according to strain and immunization protocol.

  2002cited by this paper
• Cerebral hemorrhage after passive anti-Abeta immunotherapy.

  2002cited by this paper
• Stabilities and conformations of Alzheimer's beta -amyloid peptide oligomers (Abeta 16-22, Abeta 16-35, and Abeta 10-35): Sequence effects.

  2002cited by this paper
• The challenge of inhibiting Abeta polymerization.

  2002cited by this paper
• Growth of beta-amyloid(1-40) protofibrils by monomer elongation and lateral association. Characterization of distinct products by light scattering and atomic force microscopy.

  2002cited by this paper
• Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning.

  2002cited by this paper
• Isoaspartate formation at position 23 of amyloid beta peptide enhanced fibril formation and deposited onto senile plaques and vascular amyloids in Alzheimer's disease

  2002cited by this paper
• Reversible Memory Loss in a Mouse Transgenic Model of Alzheimer's Disease

  2002cited by this paper
• Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model

  2002cited by this paper
• Enhanced antidepressant effect of sigma(1) (sigma(1)) receptor agonists in beta(25-35)-amyloid peptide-treated mice.

  2002cited by this paper
• Passive Immunization against β-Amyloid Peptide Protects Central Nervous System (CNS) Neurons from Increased Vulnerability Associated with an Alzheimer's Disease-causing Mutation*

  2002cited by this paper
• Secretases as targets for the treatment of Alzheimer's disease: the prospects.

  2002cited by this paper
• Dosing in phase II trial of Alzheimer's vaccine suspended.

  2002cited by this paper
• Non-Fc-Mediated Mechanisms Are Involved in Clearance of Amyloid-β In Vivo by Immunotherapy

  2002cited by this paper
• Brain to Plasma Amyloid-β Efflux: a Measure of Brain Amyloid Burden in a Mouse Model of Alzheimer's Disease

  2002cited by this paper
• Toxicity of beta-amyloid vaccination in patients with Alzheimer's disease.

  2002cited by this paper
• Neurodegenerative disease: Amyloid pores from pathogenic mutations

  2002cited by this paper
• Characterization of murine immunoglobulin G antibodies against human amyloid-beta1-42.

  2001cited by this paper
• A Portrait of Alzheimer Secretases--New Features and Familiar Faces

  2001cited by this paper
• Abeta immunization: moving Abeta peptide from brain to blood.

  2001cited by this paper
• The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation.

  2001cited by this paper
• Immunotherapeutic Strategies for Prevention and Treatment of Alzheimer's Disease

  2001cited by this paper
• Vaccination with soluble Aβ oligomers generates toxicity‐neutralizing antibodies

  2001cited by this paper
• Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease.

  2001cited by this paper
• Immunization against Alzheimer's beta -amyloid plaques via EFRH phage administration.

  2000cited by this paper
• A Perspective on Inflammation in Alzheimer's Disease

  2000cited by this paper
• Statins and the risk of dementia.

  2000cited by this paper
• Nasal administration of amyloid‐β peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease

  2000cited by this paper
• A Monoclonal Antibody to Amyloid Precursor Protein Induces Neuronal Apoptosis

  2000cited by this paper
• A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease.

  2000cited by this paper
• Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

  2000cited by this paper
• Immunization with beta-amyloid: could T-cell activation have a harmful effect?

  2000cited by this paper
• Amyloid fibril formation by A beta 16-22, a seven-residue fragment of the Alzheimer's beta-amyloid peptide, and structural characterization by solid state NMR.

  2000cited by this paper
• Increase of mitochondria and mitochondrial DNA in response to oxidative stress in human cells.

  2000cited by this paper
• A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease.

  2000cited by this paper
• Structure and dynamics of three-way DNA junctions: atomic force microscopy studies.

  2000cited by this paper
• Effects of Incorporation of Immunoglobulin G and Complement Component C1q on Uptake and Degradation of Alzheimer's Disease Amyloid Fibrils by Microglia*

  2000cited by this paper
• Assembly of A beta amyloid protofibrils: an in vitro model for a possible early event in Alzheimer's disease.

  1999cited by this paper
• Transfected human B cells: a new model to study the functional and immunostimulatory consequences of APP production.

  1999cited by this paper
• High avidity scFv multimers; diabodies and triabodies.

  1999cited by this paper
• Amyloid diseases: abnormal protein aggregation in neurodegeneration.

  1999cited by this paper
• Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse

  1999cited by this paper
• Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates.

  1999cited by this paper
• Artificial Antibodies for Affinity Chromatography of Homologous Proteins: Application to Blood Clotting Proteins

  1998cited by this paper
• Disaggregation of Alzheimer beta-amyloid by site-directed mAb.

  1997cited by this paper
• Observation of metastable Abeta amyloid protofibrils by atomic force microscopy.

  1997cited by this paper
• Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein

  1995cited by this paper
• Characterization of a novel protein regulated during the critical period for song learning in the zebra finch.

  1995cited by this paper
• The intracellular component of cellular 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) reduction is specifically inhibited by beta-amyloid peptides.

  1995cited by this paper
• Structure-activity analyses of beta-amyloid peptides: contributions of the beta 25-35 region to aggregation and neurotoxicity.

  1995cited by this paper
• Analysis of the autoantibody response to fibrillarin in human disease and murine models of autoimmunity.

  1995cited by this paper
• Antibody fragments from a ‘single pot’ phage display library as immunochemical reagents.

  1994cited by this paper
• Thioflavine T interaction with synthetic Alzheimer's disease β‐amyloid peptides: Detection of amyloid aggregation in solution

  1993cited by this paper
• Circular DNA molecules imaged in air by scanning force microscopy.

  1992cited by this paper
• By-passing immunization. Human antibodies from V-gene libraries displayed on phage.

  1991cited by this paper
• Improved oligonucleotide site-directed mutagenesis using M13 vectors.

  1985cited by this paper

• Tolcapone Derivative (Tol-D) Inhibits Aβ42 Fibrillogenesis and Ameliorates Aβ42-Induced Cytotoxicity and Cognitive Impairment.

  2022cites this paper
• Sex-Specific Multiparameter Blood Test for the Early Diagnosis of Alzheimer’s Disease

  2022cites this paper
• Application of Antibody Fragments Against Aβ With Emphasis on Combined Application With Nanoparticles in Alzheimer’s Disease

  2021cites this paper
• Intramuscular injection of vectorized-scFvMC1 reduces pathological tau in two different tau transgenic models

  2020cites this paper
• Engineered Extracellular Vesicles/Exosomes as a New Tool against Neurodegenerative Diseases

  2020cites this paper
• Neuronally expressed anti-tau scFv prevents tauopathy-induced phenotypes in Drosophila models.

  2020cites this paper
• Novel antibody against low‐n oligomers of tau protein promotes clearance of tau in cells via lysosomes

  2020cites this paper
• Atomic force microscopy for single molecule characterisation of protein aggregation

  2019cites this paper
• CNS disease-related protein variants as blood-based biomarkers in traumatic brain injury

  2018cites this paper
• Recombinant Antibody Fragments for Neurodegenerative Diseases

  2017cites this paper
• Developing and characterization of single chain variable fragment (scFv) antibody against frizzled 7 (Fzd7) receptor

  2017cites this paper
• APP/A&bgr; structural diversity and Alzheimer's disease pathogenesis

  2017cites this paper
• Effects of Ectoine on Behavior and Candidate Genes Expression in ICV-STZ Rat Model of Sporadic Alzheimer’s Disease

  2017cites this paper
• Conformation as the Therapeutic Target for Neurodegenerative Diseases.

  2017cites this paper
• Highly selective synthesis of substituted (E)-alkenylsilatranes via catalytic trans-silylation and mechanistic implications.

  2017cites this paper
• TDP-43 protein variants as biomarkers in amyotrophic lateral sclerosis

  2017cites this paper
• A human scFv antibody that targets and neutralizes high molecular weight pathogenic amyloid‐β oligomers

  2017cites this paper
• AFM-Based Single Molecule Techniques: Unraveling the Amyloid Pathogenic Species

  2016cites this paper
• Improved Brain Expression of Anti-Amyloid β scFv by Complexation of mRNA Including a Secretion Sequence with PEG-based Block Catiomer.

  2016cites this paper
• Aβ-Immunotherapeutic strategies: a wide range of approaches for Alzheimer's disease treatment

  2016cites this paper
• Development of new therapeutic approaches in mouse models of Amyotrophic Lateral Sclerosis

  2015cites this paper
• Kinetic analysis of IgG antibodies to beta-amyloid oligomers with surface plasmon resonance.

  2015cites this paper
• Anti-Aβ single-chain variable fragment antibodies exert synergistic neuroprotective activities in Drosophila models of Alzheimer's disease.

  2015cites this paper
• Decreasing oxidative stress and neuroinflammation with a multifunctional peptide rescues memory deficits in mice with Alzheimer disease.

  2014cites this paper
• Novel insights into amylin aggregation

  2014cites this paper
• Pan-amyloid oligomer specific scFv antibody attenuates memory deficits and brain amyloid burden in mice with Alzheimer's disease.

  2014cites this paper
• Antibodies and protein misfolding: From structural research tools to therapeutic strategies.

  2014cites this paper
• Tau aggregation and its interplay with amyloid-β

  2014cites this paper
• Probing Antibody-Antigen Interactions

  2014cites this paper
• Single-Chain Fragment Variable Passive Immunotherapies for Neurodegenerative Diseases

  2013cites this paper
• BISPECIFIC ANTIBODY FRAGMENTS FOR NEUROLOGICAL DISEASE

  2013cites this paper
• Biomolecular screening for inhibitors of butyrylcholinesterase : identification and characterization using in vitro and in silico tools

  2013cites this paper
• Central amyloid-β-specific single chain variable fragment ameliorates Aβ aggregation and neurotoxicity.

  2013cites this paper
• Characterization of a Single-Chain Variable Fragment Recognizing a Linear Epitope of Aβ: A Biotechnical Tool for Studies on Alzheimer’s Disease?

  2013cites this paper
• Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.

  2012cites this paper
• Engineered antibody approaches for Alzheimer's disease immunotherapy.

  2012cites this paper
• A Peptide Binding to the β-Site of APP Improves Spatial Memory and Attenuates Aβ Burden in Alzheimer’s Disease Transgenic Mice

  2012cites this paper
• A multifunctional peptide rescues memory deficits in Alzheimer's disease transgenic mice by inhibiting Aβ42-induced cytotoxicity and increasing microglial phagocytosis.

  2012cites this paper
• Nanobody specific for oligomeric β-amyloid stabilizes nontoxic form.

  2012influential citation
• Identification and characterization of diarylimidazoles as hybrid inhibitors of butyrylcholinesterase and amyloid beta fibril formation.

  2012cites this paper
• Dynamics of metastable β-hairpin structures in the folding nucleus of amyloid β-protein.

  2012cites this paper
• A Foldamer-Dendrimer Conjugate Neutralizes Synaptotoxic β-Amyloid Oligomers

  2012cites this paper
• Point mutations in Aβ induce polymorphic aggregates at liquid/solid interfaces.

  2011cites this paper
• Point Mutations in Aβ Result in the Formation of Distinct Polymorphic Aggregates in the Presence of Lipid Bilayers

  2011cites this paper
• Assessing mutant huntingtin fragment and polyglutamine aggregation by atomic force microscopy.

  2011cites this paper
• Silatranes: a review on their synthesis, structure, reactivity and applications.

  2011cites this paper
• Antibody-based therapy in Alzheimer's disease

  2011cites this paper
• Chronic Intranasal Treatment with an Anti-Aβ30-42 scFv Antibody Ameliorates Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease

  2011cites this paper
• Surface Plasmon Resonance Based Biosensors for Exploring the Influence of Alkaloids on Aggregation of Amyloid-β Peptide

  2011cites this paper
• Studies of the growth, evolution, and self‐aggregation of β‐amyloid fibrils using tapping‐mode atomic force microscopy

  2011cites this paper
• Intramuscular delivery of a single chain antibody gene prevents brain Aβ deposition and cognitive impairment in a mouse model of Alzheimer's disease.

  2010cites this paper
• Structure-activity relationships in peptide modulators of β-amyloid protein aggregation: variation in α,α-disubstitution results in altered aggregate size and morphology.

  2010cites this paper
• Antibody Therapy in Neurodegenerative Disease

  2010cites this paper
• Simple In Vitro Assays to Identify Amyloid-β Aggregation Blockers for Alzheimer's Disease Therapy

  2010cites this paper
• Engineered proteolytic nanobodies reduce Abeta burden and ameliorate Abeta-induced cytotoxicity.

  2010cites this paper
• Modified Immunotherapies Against Alzheimer's Disease: Toward Safer and Effective Amyloid-β Clearance

  2010cites this paper
• Rational design of amyloid β peptide–binding proteins: Pseudo‐Aβ β‐sheet surface presented in green fluorescent protein binds tightly and preferentially to structured Aβ

  2010cites this paper
• Immunotherapy in Alzheimer's Disease: Where Do We Stand? Where Should We Go?

  2010cites this paper
• Immunotherapy for Alzheimer's disease.

  2010cites this paper
• Intracellular antibodies and cancer: New technologies offer therapeutic opportunities

  2010cites this paper
• α-Tocopherol quinone inhibits β-amyloid aggregation and cytotoxicity, disaggregates preformed fibrils and decreases the production of reactive oxygen species, NO and inflammatory cytokines.

  2010cites this paper
• Design, synthesis and biological evaluation of indane-2-arylhydrazinylmethylene-1,3-diones and indol-2-aryldiazenylmethylene-3-ones as beta-amyloid aggregation inhibitors.

  2010cites this paper
• Amyloid Aggregation-Mitigating Peptides As Potential Alzheimer's Drugs

  2009cites this paper
• AFM for analysis of structure and dynamics of DNA and protein-DNA complexes.

  2009cites this paper
• Is passive immunization for Alzheimer's disease ‘alive and well’ or ‘dead and buried’?

  2009cites this paper
• Systems biology coupled with label-free high-throughput detection as a novel approach for diagnosis of chronic obstructive pulmonary disease

  2009cites this paper
• Atomic force microscopy imaging and probing of DNA, proteins, and protein DNA complexes: silatrane surface chemistry.

  2009cites this paper
• Cloning antifungal single chain fragment variable antibodies by phage display and competitive panning elution.

  2009cites this paper
• Detecting Morphologically Distinct Oligomeric Forms of α-Synuclein*

  2009cites this paper
• Intramuscular delivery of a single chain antibody gene reduces brain Abeta burden in a mouse model of Alzheimer's disease.

  2009cites this paper
• Conformation‐dependent single‐chain variable fragment antibodies specifically recognize beta‐amyloid oligomers

  2009influential citation
• Single-domain antibodies recognize selectively small oligomeric forms of amyloid beta, prevent Abeta-induced neurotoxicity and inhibit fibril formation.

  2009cites this paper
• Immunotherapeutic Strategies for Alzheimer's Disease Treatment

  2009cites this paper
• Direct in vivo intracellular selection of conformation-sensitive antibody domains targeting Alzheimer's amyloid-beta oligomers.

  2009cites this paper
• Anti-oligomeric Abeta single-chain variable domain antibody blocks Abeta-induced toxicity against human neuroblastoma cells.

  2008cites this paper
• Atomic force microscopy to characterize the molecular size of prion protein

  2008cites this paper
• Cytokine-Mediated Inhibition of Fibrillar Amyloid-β Peptide Degradation by Human Mononuclear Phagocytes1

  2008cites this paper
• A peptide containing residues 26-44 of tau protein impairs mitochondrial oxidative phosphorylation acting at the level of the adenine nucleotide translocator.

  2008cites this paper
• Antibody‐based approaches in Alzheimer’s research: safety, pharmacokinetics, metabolism, and analytical tools

  2008cites this paper
• The toxicity of beta-amyloid is attenuated by interaction with its specific human scFv E3 in vitro.

  2008cites this paper
• Epitope mapping and neuroprotective properties of a human single chain FV antibody that binds an internal epitope of amyloid-beta 1-42.

  2008cites this paper
• The Catalytic Domain of Insulin-degrading Enzyme Forms a Denaturant-resistant Complex with Amyloid β Peptide

  2008cites this paper
• Design, synthesis, and biological evaluation of glycine-based molecular tongs as inhibitors of Abeta1-40 aggregation in vitro.

  2008cites this paper
• Engineered antibody intervention strategies for Alzheimer's disease and related dementias by targeting amyloid and toxic oligomers.

  2008cites this paper
• Surface plasmon resonance and nuclear magnetic resonance studies of ABAD-Abeta interaction.

  2007cites this paper
• A cyclic peptide that binds p75NTR protects neurones from beta amyloid (1–40)‐induced cell death

  2007cites this paper
• Beta-amyloidbased immunotherapy as a treatment of Alzheimers disease.

  2007cites this paper
• Clinical immunologic approaches for the treatment of Alzheimer's disease

  2007cites this paper
• Intracellularly selected recombinant antibodies targeting β Amyloid Oligomers

  2007cites this paper
• In vivo targeting of antibody fragments to the nervous system for Alzheimer’s disease immunotherapy and molecular imaging of amyloid plaques

  2007influential citation
• Single chain antibodies against the 37 kDa/67 kDa laminin receptor as tools for prion diseases therapy

  2006cites this paper
• Anti-Abeta single-chain antibody delivery via adeno-associated virus for treatment of Alzheimer's disease.

  2006cites this paper
• Amelioration of amyloid load by anti-Abeta single-chain antibody in Alzheimer mouse model.

  2006cites this paper
• Isolation of an scFv targeting BRG1 using phage display with characterization by AFM.

  2006cites this paper
• Clearance of amyloid-beta in Alzheimer's disease: progress, problems and perspectives.

  2006cites this paper
• Immunotherapy for conformational diseases.

  2006cites this paper
• Inhibition of the formation of amyloid β‐protein fibrils using biocompatible nanogels as artificial chaperones

  2006cites this paper
• Single chain Fv antibodies against the 25-35 Abeta fragment inhibit aggregation and toxicity of Abeta42.

  2006cites this paper
• Novel approaches for immunotherapeutic intervention in Alzheimer's disease.

  2006cites this paper
• Identification and Repair of Positive Binding Antibodies Containing Randomly Generated Amber Codons from Synthetic Phage Display Libraries

  2006cites this paper